Follicle-stimulating hormone inhibits cervical cancer via NF-κB pathway
Authors Shi X, Qiu S, Zhuang W, Wang C, Zhang S, Yuan N, Yuan F, Qiao Y
Received 7 May 2018
Accepted for publication 17 June 2018
Published 14 November 2018 Volume 2018:11 Pages 8107—8115
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Arseniy Yuzhalin
Xi Shi,1,* Shiwei Qiu,1,* Wei Zhuang,1,* Caiji Wang,1 Shili Zhang,1 Na Yuan,1 Fukang Yuan,2 Yuehua Qiao1
1The Institute of Audiology and Speech Science of Xuzhou Medical College, Xuzhou 221002, People’s Republic of China; 2Department of Vascular Surgery of Xuzhou Central Hospital, Xuzhou Institute of Cardiovascular Disease, Xuzhou 221009, People’s Republic of China
*These authors contributed equally to this work
Background: Follicle-stimulating hormone (FSH) has multiple biological functions. It is currently considered that FSH can inhibit cervical cancer, and our aim was to explore the underlying molecular mechanisms.
Materials and methods: An in vivo experiment using nude mice injected with HeLa cells was performed. Flow cytometry, western blotting, and real-time quantitative PCR analyses were done.
Results: Twenty one days after injection of HeLa cells, the subcutaneous tumor mass was significantly lower (P<0.01) in mice treated with 20 mIU/mL FSH, but did not disappear. In vitro observations indicated that FSH might inhibit cell proliferation and activate cell apoptosis to induce the reduction of HeLa cells. The mRNA and protein levels of Cyclin D1, Cyclin E1, and Caspase 3 changed accordingly as expected in vivo and in vitro. Moreover, FSH inactivated the nuclear factor-kappa B (NF-κB) pathway in subcutaneous tumors; the NF-κB(p65) activity in HeLa cells was significantly decreased using 20 mIU/mL FSH and was increased when FSH was administered along with lipopolysaccharide, accompanied by the same change of cell number. Further, FSH accelerated protein kinase A (PKA) activity, but inactivated glycogen synthase kinase 3 beta (GSK-3β) activity. Specific inhibition of PKA and/or GSK-3β provided in vitro evidence that directly supported the FSH-mediated inhibition of GSK-3β to inactivate NF-κB via the promotion of PKA activity.
Conclusion: Our data are the first description of the molecular regulatory mechanisms of FSH-mediated inhibition of the development of cervical cancer by decreasing the cell cycle and activating cell apoptosis via the PKA/GSK-3β/NF-κB pathway.
Keywords: FSH, cervical cancer, cell cycle, apoptosis, PKA, NF-κB
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]